This approach is being driven by two main processes: an increased understanding ... The MRC Myeloma IX trialists defined high-risk disease by the presence of multiple adverse FISH lesions combined ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...

Carvykti shows high efficacy in real-world settings, with 89% response and 70% complete response rates among multiple myeloma patients. Despite many patients not meeting clinical trial criteria, ...

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

Dr. Terrence Bradley is a co-author. Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone ...

"We know that clinical trials have recently been investigating the combination of teclistamab and daratumumab for multiple myeloma treatment," said SU2C president and CEO Julian Adams, Ph.D. "With ...